Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Diosmetin" patented technology

Diosmetin, also known as 5,7,3'-trihydroxy-4'-methoxyflavone, is an O-methylated flavone, a chemical compound that can be found in the Caucasian vetch. It has been found to act as a weak TrkB receptor agonist.

Use of a natural small molecule compound in the preparation of a medicament for treating a disease associated with CSF1R loss of function

PendingCN122140740AOrganic active ingredientsNervous disorderDisease phenotypeDisease
The application of a natural small molecule compound in the preparation of a drug for treating a disease related to CSF1R function loss belongs to the technical field of medicine. The natural small molecule compound Diosmetin-7-O-beta-D-glucopyranoside (DDG) can effectively improve the disease phenotype of a CSF1R function loss model mouse by up-regulating the transcription and protein expression of CSF1R in microglia through enhancing the activity of a super-enhancer FIRE in the second intron of the CSF1R gene. The drug can be prepared into injection preparations, oral preparations, spray preparations, ointment preparations or patches, and provides a natural small molecule treatment scheme for diseases related to the weakening / loss of CSF1R content or function, and has a wide clinical application prospect.
Owner:XIAMEN UNIV

Application of diosmetin in preparation of medicine for treating autoimmune demyelination disease

The invention belongs to the technical field of medicines, and discloses application of diosmetin shown as a formula (I) and pharmacodynamically acceptable salts thereof in preparation of medicines for preventing, relieving and / or treating autoimmune demyelination diseases. In a mouse experimental autoimmune encephalomyelitis model, diosmetin shows a good treatment effect, and can effectively prevent and treat pathological changes and disease progression, relieve disease severity and inhibit LPS-stimulated microglial BV2 cells from releasing an inflammatory mediator, thereby providing a new drug and a new structure for clinical treatment.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI +1